A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline BRCA1 mutation (BRCA-P Study).

Bhulani, Nizar; Wood, Marie; Tsai, Joy; Bedrosian, Isabelle; Hopkins, Judith O.; Brunet, Joan; Michaelson-Cohen, Rachel; Schmutzler, Rita K.; Evans, Gareth D; Gnant, Michael; Fesl, Christian; Mystek, Aleksandra; Lindeman, Geoffrey J; Singer, Christian F.; Garber, Judy Ellen

doi:10.1200/jco.2022.40.16_suppl.tps10616

A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline BRCA1 mutation (BRCA-P Study).

TPS10616 Background: Women with BRCA1 mutations have a 50-70% lifetime risk of developing breast cancer. Currently, prophylactic mastectomy is the only strategy that significantly reduces breast cancer risk. Recent evidence suggests that the RANK/RANKL signaling pathway plays a pivotal role in th…